Expert - Boris Peaker

"We maintain our Perform rating on ONC."

— Boris Peaker, Oppenheimer & Co. (9/13/12)
more >

"The Reolysin Phase 3 study remains the key value driver for ONC."

— Boris Peaker, Oppenheimer & Co. (8/2/12)
more >

Due to permission requirements, not all quotes are shown.